MichelleLofwallMD

Associate Professor, Behavioral Science, University of Kentucky College of Medicine

Dr. Lofwall is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
845 Angliana Ave
Lexington, KY 40508
Phone+1 859-323-9321

Fax+1 859-257-5232

Johns Hopkins University/Bayview Medical CenterFellowship, Addiction Medicine, 2003 - 2004
Johns Hopkins UniversityResidency, Psychiatry, 1999 - 2003
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1999

PubMed

86 citations
Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations.
Marion A. Coe, Michelle R. Lofwall, Sharon L. Walsh
Journal of Addiction Medicine. 2019-03-01
27 citations
Substance Use Disorder Assessment, Diagnosis, and Management for Patients Hospitalized With Severe Infections Due to Injection Drug Use.
Crystal Jicha, David Saxon, Michelle R. Lofwall, Laura C. Fanucchi
Journal of Addiction Medicine. 2019-01-01
30 citations
Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers
Sharon L. Walsh, Markus Heilig, Paul A. Nuzzo, Pam Henderson, Michelle R. Lofwall
Addiction Biology. 2013-03-01

Lectures

Different Faces of Substance Abuse Annual Conference 2013
The Different Faces of Substance Abuse, Lexington, Kentucky - 1/23/2013

Biden Relaxes Buprenorphine Prescribing but Pharmacies Aren’t BitingMay 5th, 2021
Confronting an Opioid Crisis and Promoting Health from All AnglesNovember 2nd, 2020
How to Make the Opioid Epidemic Worse in PennsylvaniaDecember 6th, 2019
Join now to see all